Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Lochner Daniel reported acquisition or exercise transactions in this Form 4 filing.
Tectonic Therapeutic, Inc. Chief Financial Officer Daniel Lochner reported equity awards on March 4, 2026. He received 26,500 shares of common stock in the form of restricted stock units that vest in three equal annual installments on March 4, 2027, March 4, 2028 and March 4, 2029, contingent on continued service. He was also granted an employee stock option for 24,250 shares, vesting in 48 equal monthly installments beginning on April 4, 2026, also subject to continued service, bringing his directly held common stock to 58,544 shares after the award.
Ruddy Marcella K. reported acquisition or exercise transactions in this Form 4 filing.
Tectonic Therapeutic, Inc. Chief Medical Officer Marcella K. Ruddy reported equity awards on March 4, 2026. She received 26,500 shares of common stock in the form of restricted stock units that vest in three equal annual installments on March 4, 2027, 2028 and 2029, subject to continued service. She was also granted an option for 24,250 shares, vesting in 48 equal monthly installments beginning April 4, 2026. Following these awards, her directly held common stock totaled 79,747 shares.
Tectonic Therapeutic, Inc. director and Chief Executive Officer Alise Reicin reported that the Reicin-Boiarsky Family Trust, a trust associated with her, bought 2,500 shares of common stock in an open-market purchase on February 11, 2026 at a weighted average price of $21.10 per share.
Following this transaction, the trust holds 127,030 shares with indirect ownership attributed to Reicin, while she also directly owns 235,047 shares of common stock.
TECX proposes sale of common shares under Rule 144. The filing lists 1,650 restricted stock units with an award date of 02/04/2026 and a proposed sale date of 03/04/2026. It also records 1,649 shares sold under a 10b5-1 plan on 03/03/2026.
Tectonic Therapeutic, Inc. joint statement reports beneficial ownership positions held by TCG Crossover entities and Chen Yu.
TCG Crossover II and TCG Crossover III each hold 584,882 and 584,878 shares respectively; the Reporting Individual, Chen Yu, is reported as beneficially owning 1,169,760 shares, equal to 6.2% of the class based on 18,776,626 shares outstanding as of February 16, 2026, per the issuer's Form 10-K.
Tectonic Therapeutic, Inc. reported a larger net loss as it ramped R&D to advance two lead programs while strengthening its balance sheet. For the quarter ended December 31, 2025, net loss was $19.2 million, versus $12.4 million a year earlier, with research and development expenses rising to $16.3 million from $9.2 million. Full-year 2025 net loss was $74.2 million.
Cash and cash equivalents reached $253.8 million as of December 31, 2025, up from $141.2 million a year earlier, and are expected to fund operations into Q4 2028, including Phase 2 readouts for TX45 and development of TX2100. TX45 delivered positive Phase 1b data in Group 2 pulmonary hypertension, showing a 29.2% reduction in pulmonary capillary wedge pressure and a 17.3% improvement in cardiac output, and has moved into multiple Phase 2 trials. TX2100 entered a Phase 1a trial in healthy volunteers in February 2026 targeting hereditary hemorrhagic telangiectasia.
Tectonic Therapeutic is a clinical-stage biotech company developing biologic drugs that target G‑protein coupled receptors (GPCRs) using its proprietary GEODe™ discovery platform. It focuses on serious diseases with limited treatment options, particularly cardiovascular, pulmonary and genetic bleeding disorders.
The lead program, TX45, is an Fc‑relaxin fusion targeting the RXFP1 GPCR for Group 2 pulmonary hypertension with heart failure with preserved ejection fraction (PH‑HFpEF) and related indications. Phase 1a in healthy volunteers showed TX45 was well‑tolerated with a 14–20 day half‑life and a 33% increase in renal plasma flow, supporting subcutaneous dosing regimens. In PH‑HFpEF and PH‑HFrEF Phase 1b studies, single IV doses produced double‑digit percentage reductions in pulmonary capillary wedge pressure and pulmonary vascular resistance and improvements in cardiac output, without serious or severe adverse events.
An ongoing global APEX Phase 2 trial in PH‑HFpEF is testing 300 mg TX45 given subcutaneously every two or four weeks, enrolling about 180 patients and using change in pulmonary vascular resistance in combined pre‑ and post‑capillary PH as the primary endpoint. Tectonic is also launching a 16‑week open‑label Phase 2 study of TX45 in Group 3 pulmonary hypertension associated with interstitial lung disease, using change in pulmonary vascular resistance at Week 16 as the primary endpoint.
The second clinical asset, TX2100, is a long‑acting APJ VHH‑Fc fusion antagonist antibody in development for hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder with no approved therapies. Preclinical HHT models showed reduced arteriovenous malformation formation, bleeding and anemia, and 13‑week toxicology in non‑human primates found no target‑related toxicities at doses up to 100 mg/kg/week. A Phase 1a randomized, placebo‑controlled, ascending‑dose trial in healthy volunteers began in February 2026, with plans for Phase 2 trials in moderate to severe HHT and a Phase 1b study in severe HHT starting in early 2027.
Tectonic’s GEODe™ platform combines engineered GPCRs, optimized yeast Fab/VHH libraries and structure‑guided protein engineering to discover GPCR‑targeted biologics. The company reports multiple patent families covering TX45, TX2100 and its platform, with expected expiries ranging from May 2041 to at least August 2045. As of June 30, 2025, non‑affiliate common equity had an aggregate market value of $232.0 million, and as of February 16, 2026, there were 18,776,626 shares of common stock outstanding.
Tectonic Therapeutic, Inc. is expanding and reshaping its board leadership while advancing its lead bleeding-disorder program TX2100. The board increased its size from six to seven directors and appointed industry veteran François Nader, M.D. as an independent Class III director, effective April 1, 2026, when he will also become Chair of the Board.
Current Chair Terry McGuire will step down as Chair on April 1, 2026 and remain a director until the 2026 annual stockholder meeting. As a non-employee director and Chair, Dr. Nader will receive cash retainers and an option to purchase 20,400 shares, with additional annual equity in line with the company’s compensation policy. Tectonic also highlighted TX2100, a potential first-in-class APJ antagonist for hereditary hemorrhagic telangiectasia, now in an ongoing Phase 1a trial in healthy volunteers, with Phase 1b and Phase 2 studies planned.
Tectonic Therapeutic, Inc. Chief Executive Officer and director Alise Reicin reported an open-market purchase of 2,500 shares of common stock on February 11, 2026. The shares were bought at a weighted average price of $21.10 per share, with individual trades ranging from $21.02 to $21.15.
Following this transaction, Reicin directly holds 237,547 common shares. In addition, 124,530 common shares are held indirectly by the Reicin-Boiarsky Family Trust, where her spouse is a co-trustee. She may be deemed to share voting and dispositive power over the trust’s shares but disclaims beneficial ownership beyond her pecuniary interest.